Our Company
Presentation
Presentation post-ASCO
Half-year results 2022
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
OSE-127
FR104
BI 765063
OSE-230
CLEC-1
BiCKI®
Research & Development
Scientific publications
Investors
Press Releases
Regulated information
Financial documents
General Shareholders’ meetings
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Contact
en
fr
Retour aux communiqués
Date
OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104
Téléchargez